JSAM
AMLX icon

J. Safra Asset Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

J. Safra Asset Management’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.66K Sell
315
-62
-16% -$959 ﹤0.01% 475
2026
Q1 		$5.24K Buy
377
+254
+207% +$3.57K ﹤0.01% 460
2025
Q4 		$1.49K Buy
+123
New +$1.67K ﹤0.01% 605

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

J. Safra Asset Management's AMLX Position: Q2 2026 in Review

J. Safra Asset Management reduced its Amylyx Pharmaceuticals (AMLX) stake by 16% in Q2 2026, selling an estimated $959 and leaving 315 shares worth $5.66K. The position accounts for ﹤0.01% of the portfolio, ranked #475.

J. Safra Asset Management first reported a position in AMLX in Q4 2025 and has held it in 3 quarters since. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • J. Safra Asset Management held 315 shares of Amylyx Pharmaceuticals worth $5.66K as of Q2 2026.
  • J. Safra Asset Management sold 62 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $959.
  • Amylyx Pharmaceuticals made up ﹤0.01% of J. Safra Asset Management's portfolio in Q2 2026, its #475 holding.
  • J. Safra Asset Management first reported a position in Amylyx Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on J. Safra Asset Management's 13F filing for Q2 2026, filed 6 Aug 2026.